Table. Reconciliation of results of current and prior meta-analyses.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Current meta-analysis | Huang  2019 PMID 31296196 | Rota 2019  PMID: 31046087 | Wang 2018  PMID 2997938 | Snowsill (NHS)\*, 2018 PMID 26013989 | Coureau 2016 PMID: 27211572 | Usman Ali 2016  PMID: 2713053 | Fu 2014  PMID 25307063 | Manser (Cochrane), 2013 PMID 23794187 | Humphrey (USPSTF) 2013  PMID: 23897166 |
| Number of studies | 9 | 9 | 7 | 4 | 4 | 5 | 4 | 4 | 1 | 4 |
| Efficacy for lung cancer mortality reduction | 0.84 (0.75, 0.93) | 0.83 (0.76, 0.90) | 0.80 (0.71, 0.90) | 1.13 (0.78, 1.64)  Exclude MILD  1.02 (0.66, 1.58) | 0.94 (0.74, 1.19)  Exclude MILD  0.85 (0.74, 0.98) | Meta-analysis not performed due to lack of power, methodologic heterogeneity | Annual vs. usual  1.30 (0.81, 2.11)  CXR  Biennial vs. usual  1.45 (0.79, 2.69)  LDCT vs. CXR (n = 1)  0.80 (0.70, 0.92) | 0.84 (0.74, 0.96) Studies mislabeled | 0.80 (0.70, 0.92) | Meta-analysis not performed due to heterogeneity |
| Heterogeneity | 0% | 1% | 19% | 87%  Excluding MILD 85% | 43%  6.9% | Not estimated | 40%  NA  NA | 48% | Not applicable (1 study) | High |
| Efficacy for overall mortality reduction | 0.96 (0.91, 1.01) | 0.95 (0.90, 1.00) | Not reported | Not reported | 1.00 (0.87, 1.16)  Exclude MILD  0.95 (0.89, 1.00) | Meta-analysis not performed due to lack of power, methodologic heterogeneity | Annual LDCT vs. usual  1.38 (0.86, 2.22)  Biennial vs. usual 1.45 (0.79, 2.69)  LDCT vs. CXR 0.94 (0.88, 0.998) | 1.04 (0.72, 1.51)  Studies mislabeled | 0.94 (0.88, 1.00) | Meta-analysis not performed due to heterogeneity |
| Heterogeneity | 0% | 0% | Not reported | Not reported | 57%  0% | Not estimated | 80%  NA  NA | 48% | Not applicable (1 study) | High |